Medulloblastoma: molecular pathways and histopathological classification

Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline

The revised WHO classification of tumors of the CNS 2016 has introduced the concept of the integrated diagnosis. The definition of medulloblastoma entities now requires a combination of the traditional histological information with additional molecular/genetic features. For definition of the histopathological component of the medulloblastoma diagnosis, the tumors should be assigned to one of th...

Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.

This study examined the utility of stratifying children with medulloblastomas by a combination of refined histopathological classification and molecular cytogenetic evaluation. Detailed histopathological classification of tumors from a cohort of patients (n = 87) composed mainly of children entered into the International Society of Pediatric Oncology (SIOP)/United Kingdom Children's Cancer Stud...

Pediatric Medulloblastoma: Molecular biology, correlation with histopathological and clinical Submitted for MCh Neurosurgery Sree

Medulloblastoma: from molecular pathology to therapy.

Medulloblastoma is the most common malignant tumor of central nervous system in children. Patients affected by medulloblastoma may be categorized as high-risk and standard-risk patients, based on the clinical criteria and histologic features of the disease. Currently, multimodality treatment, including surgery, radiotherapy, and chemotherapy is considered as the most effective strategy against ...

G-protein coupled receptor expression patterns in medulloblastoma subgroups: identifying and exploiting molecular targets

Genome-wide association studies have identified several subgroups of medulloblastoma; however, few druggable targets have emerged. G-protein coupled receptors (GPCRs) possess characteristics that make them ideal targets for molecular imaging and therapeutics; drugs targeting GPCRs account for 30-40% of all current pharmaceuticals. While expression patterns of many proteins in human medulloblast...